LAVAL, QC, Jan. 29 /PRNewswire-FirstCall/ - Labopharm Inc. today announced that James R. Howard-Tripp, President and Chief Executive Officer of the Company, will present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference in New York on Wednesday, February 7, 2007 at 1:00 p.m. ET.
Mr. Howard-Tripp’s presentation will focus on Labopharm’s continued progress in the global commercialization of its once-daily formulation of tramadol.
A live webcast of the presentation will be available on Labopharm’s website at www.labopharm.com. Please connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. The webcast will be archived at the above website for 14 days.
About Labopharm Inc.
Labopharm Inc. is an international specialty pharmaceutical company focused on the development of drugs incorporating the Company’s proprietary advanced controlled-release technologies. The Company’s lead product, a once-daily formulation of the analgesic tramadol, has been approved and launched in Europe and is currently under review for approval by the U.S. Food and Drug Administration. For more information, please visit www.labopharm.com.
This press release contains forward-looking statements, which reflect the Corporation’s current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual events could differ materially from those projected herein and depend on a number of factors, including the uncertainties related to the regulatory process and the commercialization of the Corporation’s products thereafter. Investors should consult the Corporation’s ongoing quarterly filings and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. The Corporation disclaims any obligation to update these forward-looking statements.
Labopharm Inc.
CONTACT: please contact: At Labopharm: Mark D’Souza, Chief FinancialOfficer, Tel: (450) 686-0207; At The Equicom Group: Jason Hogan, Media andInvestor Relations, Tel: (416) 815-0700, jhogan@equicomgroup.com; French:Eric Bouchard, Tel: (514) 208-5939, ebouchard@equicomgroup.com
